ENहिन्दी soon
Home/India/Answers/Zepbound in India
INIndia News and rules

Is Zepbound available in India?

GLP Guidebook teamUpdated 5 Oct 202617 sourcesWritten from published sources
The short answer

No. Zepbound is Eli Lilly's brand of tirzepatide for weight in the US and Japan, and we found no Indian launch. India sells the same medicine as Mounjaro, approved here for type 2 diabetes and weight management, and as Cipla's Yurpeak. On 5 October 2026, the 2.5 mg Mounjaro KwikPen's printed MRP was ₹13,125.

Before you go further
  • GLP‑1 medicines, tirzepatide included, are prescription-only in India, not sold over the counter.13
  • A government statement on 1 Apr 2026 said only endocrinologists, internal-medicine specialists and cardiologists can prescribe them.13 CDSCO expert-committee minutes attach a similar condition to some approvals (endocrinologist or internal-medicine specialist), but we found no rule covering every brand.6
  • The risks are in Guide 5: Side effects and risks.
  • Nothing here promises any result, and nothing here is for sale.

What is Zepbound?

Zepbound is Eli Lilly's brand of tirzepatide for weight in the US and Japan, first approved by the US regulator (FDA) on 8 November 2023.2

The US label covers long-term weight loss in adults with obesity, or overweight plus at least 1 weight-related condition. It also covers moderate to severe sleep apnoea (obstructive sleep apnoea) in adults with obesity.1 Japan approved it for obesity with related health problems on 27 December 2024, and it went on sale there on 11 April 2025.16,17 In the US, Lilly's other tirzepatide brand, Mounjaro, is labelled for type 2 diabetes.3 The Zepbound label says not to combine it with other tirzepatide products.1

How is tirzepatide sold in India?

In India, Lilly sells tirzepatide as Mounjaro, launched on 20 March 2025 and approved here for both type 2 diabetes and weight management.

A CDSCO expert committee first recommended tirzepatide in April 2023.6 In June 2024 it recommended the weight use too, if Lilly runs a follow-up (Phase IV) trial.7 Lilly launched Mounjaro after CDSCO's approval.4,5 Its weight use covers adults with a BMI of 30 or more, or 27 or more with a weight-related condition.5 India defines obesity lower, from a BMI of 25.15 Those numbers come from the approval, and a doctor decides what they mean for you.

Cipla has sold a second brand, Yurpeak, since 10 December 2025. Lilly makes it, and Cipla says the price matches Mounjaro.8 How the two medicines compare is in Mounjaro vs Ozempic.

What does tirzepatide cost in India?

On 5 October 2026, Mounjaro KwikPens had printed MRPs from ₹13,125 (2.5 mg) to ₹25,781 (12.5 mg and 15 mg), for 4 weekly doses.10

Lilly launched the pens at ₹14,000 to ₹27,500 for a month's supply.9 GST on most medicines fell from 12% to 5% on 22 September 2025.11 The drug-price regulator (NPPA) told makers to revise MRPs from that date.12 Today's MRPs equal the launch prices with the lower tax worked in. That is our arithmetic; we found no Lilly statement.

We count a year as 52 weekly doses. At 5 mg (₹16,406 a pen), that is 13 pens, about ₹2.13 lakh.10 Which strength applies is a doctor's call; Mounjaro doses explained covers the steps. Every strength is in What is the MRP of Mounjaro in India?.

Work out a full year's cost

Medicine, doctor visits and tests, in ₹. Free, no sign-up.

Open the calculator

Can you import Zepbound for personal use?

India's drug rules let a traveller bring in up to 100 average doses of a medicine for their own use; posted imports need a permit.

Rule 36 of the Drugs Rules, 1945 (made under the Drugs and Cosmetics Act) says the medicine must be in your bona fide baggage. It must be declared to Customs if they ask.14 Posted or couriered medicine needs a permit, applied for on Form 12A with a prescription and issued on Form 12B.14

A Zepbound single-dose pen is stored at 2–8°C and may spend at most 21 days out of the fridge, at no more than 30°C. The US KwikPen allows up to 30 days at up to 30°C.1 That is hard to check for a pen that came by post. Pens from unknown sellers can also be fake; see fake GLP-1 pens in India. The full picture of brands and doctors is in Guide 6.

RisksThe risks, in brief
  • Stomach effects. In the US Zepbound label's weight trials, 25% to 29% on 5 mg to 15 mg felt sick (nausea). On a dummy injection, 8% did.1
  • A swollen pancreas (pancreatitis) and gallbladder disease are label warnings.1
  • Kidneys. Dehydration from vomiting or diarrhoea can harm the kidneys (acute kidney injury), a US Zepbound label warning.1
  • Thyroid C-cell tumour warning. The US label rules it out with a personal or family history of a rare thyroid cancer (MTC) or MEN 2; tell your doctor if this applies.1
  • Pregnancy and the pill. It may harm an unborn baby, and the label says to stop once pregnancy is known. It can make the contraceptive pill less reliable for 4 weeks after starting and after each dose rise.1
Full detail in Guide 5: Side effects and risks →

Read the full picture

Related questions

Is Mounjaro available in India? What is tirzepatide? Is there a generic Mounjaro (tirzepatide) in India? Do you need a prescription for GLP-1 medicines in India? Can you carry an Ozempic or Mounjaro pen on a flight?
Did this answer your question?

Sources

  1. Eli Lilly. Zepbound (tirzepatide) US prescribing information, revised 08/2026. US label; we found no Indian launch of Zepbound. Boxed warning; sections 1, 4, 5 (incl. 5.3), 6.1 (Table 1), 8.1, 8.3, 16.2 (single-dose pen; single-patient-use KwikPen). accessdata.fda.gov (PDF)
  2. US FDA. Drugs@FDA: NDA 217806, Zepbound (tirzepatide), Eli Lilly. Original approval 11/08/2023. accessdata.fda.gov
  3. Eli Lilly. Mounjaro (tirzepatide) US prescribing information, revised 08/2026, section 1. US label, not the Indian one. pi.lilly.com
  4. Business Standard (Sohini Das, with Reuters). Eli Lilly launches Mounjaro in India, 20 Mar 2025. business-standard.com
  5. Indian Pharma Post. Lilly launches Mounjaro in India for treatment of obesity and type 2 diabetes (Lilly India launch statement), 24 Mar 2025. indianpharmapost.com
  6. CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), 100th meeting, 20–21 Apr 2023, item 1 (tirzepatide, Eli Lilly). Committee minutes, not the final permission. cdsco.gov.in (PDF) · archived copy
  7. CDSCO. Recommendations of the SEC (Endocrinology & Metabolism), 12th/24 meeting, 19 Jun 2024, item 3 (tirzepatide pens and vials, additional indication: chronic weight management, "subject to condition that firm should conduct Phase-IV clinical trial"). cdsco.gov.in (PDF) · archived copy
  8. Cipla Ltd. Cipla launches Yurpeak (tirzepatide) for the treatment of obesity and type 2 diabetes. Press release, 10 Dec 2025. cipla.com (PDF)
  9. Business Standard (citing Reuters). Mounjaro KwikPen by Lilly debuts in India at ₹14,000 for diabetes, obesity, 13 Aug 2025. business-standard.com
  10. PharmEasy, MrMed and Tata 1mg product listings, printed MRPs of Mounjaro KwikPens: 2.5 mg ₹13,125; 5 mg ₹16,406 (MrMed ₹16,406.25); 12.5 mg and 15 mg ₹25,781 (MrMed ₹25,781.25). Pharmacy listings, used only for the printed MRP, checked 5 Oct 2026.
  11. Press Information Bureau, Ministry of Finance. Recommendations of the 56th meeting of the GST Council, 3 Sep 2025 ("Reduction of GST on all other drugs and medicines from 12% to 5%"; from 22 Sep 2025). gstcouncil.gov.in (PDF)
  12. NPPA Office Memorandum F. No 12(24)/2021/DP/NPPA/Div.II(Vol.II)-Part(1), 12 Sep 2025: revise MRPs from 22 Sep 2025 in line with the GST cut. Summary by CliniExperts. cliniexperts.com
  13. PIB Research (Government of India). GLP-1 Drugs: Use, Risks, and Regulation. Backgrounder, 1 Apr 2026. pib.gov.in (PDF)
  14. CDSCO. The Drugs Rules, 1945, as amended to G.S.R. 360(E), 1 Jul 2024 (consolidated text), Rule 36 (Import of drugs for personal use) and Forms 12A and 12B, pp. 23–24. cdsco.gov.in (PDF) · archived copy
  15. Misra A et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians. J Assoc Physicians India 2009;57:163-70. PMID 19582986
  16. Eli Lilly Japan K.K. and Mitsubishi Tanabe Pharma. Zepbound approved in Japan for "obesity disease", press release, 27 Dec 2024. tanabe-pharma.com (PDF)
  17. Eli Lilly Japan K.K. and Mitsubishi Tanabe Pharma. NHI price listing and release date (11 Apr 2025) of Zepbound, press release, 19 Mar 2025. tanabe-pharma.com (PDF)

Last checked 5 Oct 2026 · Next review due 5 Apr 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above. We checked each MRP on 5 Oct 2026 and used only printed MRPs, never a seller's discount price. It's general information, not medical advice. Talk to a qualified doctor before starting, stopping or changing any medicine. How we write